Chronic laryngitis

Summary

Chronic laryngitis (MONDO:0001369) is a disease with 6 GWAS associations across 4 studies and 2 clinical trials. Top therapeutic interventions include esomeprazole. A subtype of laryngitis — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• GWAS associations: 6
• Clinical trials: 2

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	chronic laryngitis
Mondo ID	MONDO:0001369
DOID	DOID:11797
ICD-10-CM	J37.0
ICD-11	2009723608
NCIT	C26975
SNOMED CT	29951006
UMLS	C0155836
MedGen	102342
Is cancer (heuristic)	no

Also known as: laryngitis, chronic

Data availability: 6 GWAS associations (4 studies).

Disease family

This is a subtype of laryngitis. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › respiratory system disorder › upper respiratory tract disorder › laryngeal disorder › laryngitis › chronic laryngitis

Related subtypes (3): laryngotracheitis, acute laryngitis, laryngeal tuberculosis

Genetics & variants

GWAS landscape

6 GWAS associations across 4 studies. Top hits map to 4 distinct genes (as reported by GWAS).

Top associations by p-value

rsID	p-value	Gene	Risk allele	Odds ratio
rs565266096	1e-14	RORB	G	3.43
rs187967316	7e-14	NDST4	T	4.4
rs184756987	8e-13	SS18	C	2.18
rs572966339	4e-12	LINC02466	C	4.09
rs144067010	1e-11	CBX1P3 - LINC00303	T	3.75
rs796920051	4e-11	SPATC1L - LSS	C	4.45

Top studies (by case count)

Study	Lead author	Year	Cases	Controls	Title
GCST90478090	Verma A	2024	903	447,899	Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program.
GCST90480234	Verma A	2024	247	121,015	Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program.
GCST90482063	Verma A	2024	247	121,015	Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program.
GCST90436198	Zhou W	2018	104	390,045	Efficiently controlling for case-control imbalance and sample relatedness in large-scale genetic association studies.

Variant details and genetic-evidence tiers

Tier distribution (top 50 variants)

Tier	Variants
Tier 1: coding	0
Tier 2: splice/UTR	0
Tier 3: regulatory	0
Tier 4: intronic/intergenic	6

MAF distribution

Bucket	Variants
common (>=0.05)	0
low_freq (0.01-0.05)	0
rare (<0.01)	6
unknown	0

Functional consequences

Consequence	Count
intron_variant	4
intergenic_variant	1
non_coding_transcript_exon_variant	1

Top variants

rsID	Chr	Pos	Alleles	MAF	Consequence	Gene	p-value	Tier
rs565266096	9	74630433	G>A,T	0	intron_variant	RORB	1e-14	Tier 4: intronic/intergenic
rs187967316	4	114913365	T>C	0.001	intron_variant	NDST4	7e-14	Tier 4: intronic/intergenic
rs184756987	18	26084052	C>A,G	0.001	intron_variant	SS18	8e-13	Tier 4: intronic/intergenic
rs572966339	4	129677938	C>T	0	intron_variant	LINC02466	4e-12	Tier 4: intronic/intergenic
rs144067010	1	203978674	T>A,C,G	0	intergenic_variant	CBX1P3 - LINC00303	1e-11	Tier 4: intronic/intergenic
rs796920051	21	46185113	C>T	0	non_coding_transcript_exon_variant	SPATC1L - LSS	4e-11	Tier 4: intronic/intergenic

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 2.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01389401	Not specified	COMPLETED	Salivary Epidermal Growth Factor (EGF) Concentration Before and After Treatment of Reflux Laryngitis
NCT01806220	Not specified	COMPLETED	Laryngeal and Esophageal EGF-r Expression in Patients With Reflux Laryngitis

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
ESOMEPRAZOLE	4	1